Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Malignant Neoplasm in the Bone: early-phase trial registry
7 of 17 indexed Metastatic Malignant Neoplasm in the Bone trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 7 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Metastatic Malignant Neoplasm in the Bone: 17 US clinical trials tracked, 7 recruiting.
Metastatic Malignant Neoplasm in the Bone is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition metastatic-malignant-neoplasm-in-the-bone
OPEN 7 | RECR 41% | LATE 3 | EARLY 9 | RANK #1004 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)
Metastatic Malignant Neoplasm in the Bone lists 7 open slots (41% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Malignant Neoplasm in the Bone on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Malignant Neoplasm in the Bone is recruiting below its size-band peers.
7 of 17 indexed trials (41.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Malignant Neoplasm in the Bone research.
National Cancer Institute (NCI) accounts for 5 of 17 trials (29.4%). 10 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Malignant Neoplasm in the Bone enrolment sits around 70 participants.
Median target enrolment is 70 among the 17 trials that report a genuine target (sentinel values excluded). 10 of those (58.8%) plan for fewer than 100 participants.
-
Metastatic Malignant Neoplasm in the Bone research is mostly interventional.
15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
University of Washington
NCT01050504
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
NRG Oncology
NCT06745024
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
University of Southern California
NCT03858205
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
NCT04071236
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
NCT04489719
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
NCT04693377
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
NCT06549478
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
NCT03793166
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Cancer Institute (NCI)
NCT02306161
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
NCT04071223
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
National Cancer Institute (NCI)
NCT04090398
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
University of Utah
NCT03796767
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
NCT05924672
Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
Wake Forest University Health Sciences
NCT02699697
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
NCT02099864
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03204812
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
NCT03749460
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Malignant Neoplasm in the Bone records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Malignant Neoplasm in the Bone trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Malignant Neoplasm in the Bone page
17 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Metastatic Malignant Neoplasm in the Bone trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Malignant Neoplasm in the Bone trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Malignant Neoplasm in the Bone condition card totals 17 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.